Lymphoma is listed among the neoplasias with a high risk of venous thromboembolism
(VTE). Risk factors for VTE appear to differ from risk factors in solid tumors. We review the …

Thrombosis and bleeding are commonly observed in cancer patients, and their
management is crucial for positive patient outcomes. A comprehensive, prophylactic, and …

Cancer-associated thrombosis (CAT) is a leading cause of death in cancer patients
receiving outpatient chemotherapy. The latest guidelines emphasize stratifying the patients …

Patients with cancer are at increased risk of venous thromboembolism (VTE). Risk
assessment models can help identifying high-risk populations that might benefit from …

Venous (VTE) and arterial (ATE) thromboemboli are a leading cause of morbidity and
mortality in patients with cancer. Patients with hematological malignancies are at an …

Simple Summary Cancer patients are at greater risk of developing venous
thromboembolism compared to the general population, which can lead to a decreased …

Background The incorporation of genetic variables into risk scores for predicting venous
thromboembolic events (VTE) could improve their capacity to identify those patients for …

Lymphoma-associated venous thromboembolism (VTE) can be a serious complication in
lymphoma patients. We designed a nomogram as a guide to estimate the VTE risk in …

Patients with hematologic malignancy have an increased risk of venous thromboembolism
(VTE) compared to the general population. This risk is highest during the first months after …

Background: Venous thromboembolism (VTE) is a potential complication among lymphoma
patients. We evaluated the incidence rate and predictors of VTE in lymphoma patients …